drugset / Trial / NCT03246347
A Trial of Androgen Deprivation, Docetaxel, and Enzalutamide for Metastatic Prostate Cancer
Phase 2
Active not recruiting
40 enrolled
Wake Forest University Health Sciences
Astellas Pharma Inc · collabMedivation, Inc. · collab
NaSingle-groupOpen-labelTreatment
Summary
This is a study with the combination of androgen deprivation therapy (ADT) and docetaxel with the addition of enzalutamide in the treatment of subjects with metastatic prostate cancer. The purpose of this study is to assess if ADT + docetaxel + enzalutamide is well tolerated and demonstrates improved efficacy compared to ADT + docetaxel.
Timeline
- Start
- 2017-08-23
- Primary completion
- 2022-09-01
- Completion
- 2028-03
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Docetaxel | Small molecule | — | — |
| Subject | Enzalutamide | Other / unclassified | — | — |